GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 250,300 shares, a growth of 35.8% from the February 13th total of 184,300 shares. Based on an average trading volume of 850,600 shares, the days-to-cover ratio is presently 0.3 days. Currently, 11.2% of the company’s shares are short sold.

GT Biopharma Price Performance

GTBP traded down $0.16 during midday trading on Monday, reaching $2.40. 91,745 shares of the company’s stock traded hands, compared to its average volume of 581,223. The firm has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.49. The stock has a market capitalization of $6.09 million, a price-to-earnings ratio of -0.34 and a beta of 0.59. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Roth Mkm assumed coverage on GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 target price for the company. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a report on Monday, December 2nd.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.